Preclinical Pharmacology and Toxicology of Intravenous MV-NIS, an Oncolytic Measles Virus Administered With or Without Cyclophosphamide
- 31 October 2007
- journal article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 82 (6) , 700-710
- https://doi.org/10.1038/sj.clpt.6100409
Abstract
MV‐NIS is an oncolytic measles virus encoding the human thyroidal sodium iodide symporter (NIS). Here, we report the results of preclinical pharmacology and toxicology studies conducted in support of...Keywords
This publication has 39 references indexed in Scilit:
- Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinomaHepatology, 2006
- Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responsesProceedings of the National Academy of Sciences, 2006
- Dual Therapy of Ovarian Cancer Using Measles Viruses Expressing Carcinoembryonic Antigen and Sodium Iodide SymporterClinical Cancer Research, 2006
- Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft modelCancer Gene Therapy, 2006
- Cyclophosphamide Allows for In vivo Dose Reduction of a Potent Oncolytic VirusCancer Research, 2005
- Rescue and propagation of fully retargeted oncolytic measles virusesNature Biotechnology, 2005
- Oncolytic measles viruses for cancer therapyExpert Opinion on Biological Therapy, 2004
- Biodistribution of Oncolytic Measles Virus After Intraperitoneal Administration into Ifnar™-CD46Ge Transgenic MiceHuman Gene Therapy, 2003
- Restriction of Measles Virus RNA Synthesis by a Mouse Host Cell Line: trans -Complementation by Polymerase Components or a Human Cellular Factor(s)Journal of Virology, 2002
- Comparison of sequences of the H, F, and N coding genes of measles virus vaccine strainsVirus Research, 1994